The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis

Infect Immun. 2006 May;74(5):3039-41. doi: 10.1128/IAI.74.5.3039-3041.2006.

Abstract

We have previously shown that vaccination with a vaccine based on the recombinant N-terminal domain of Als1p (rAls1p-N) protected BALB/c mice against disseminated infection caused by a single strain of Candida albicans (A. S. Ibrahim, B. J. Spellberg, V. Avenissian, Y. Fu, S. G. Filler, and J. E. Edwards, Jr., Infect. Immun. 73:999-1005, 2005, and B. J. Spellberg, A. S. Ibrahim, V. Avenissian, S. G. Filler, C. Myers, Y. Fu, and J. E. Edwards, Jr., Infect. Immun. 73:6191-6193, 2005). Here we show that the rAls1p-N vaccine also improves survival of outbred mice from disseminated candidiasis and that it is active against multiple virulent strains of C. albicans and non-C. albicans spp.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Candida / immunology*
  • Candidiasis / microbiology
  • Candidiasis / mortality
  • Candidiasis / therapy*
  • Fungal Proteins / immunology*
  • Fungal Vaccines / immunology*
  • Mice
  • Mice, Inbred BALB C
  • Recombinant Proteins / immunology
  • Vaccination
  • Vaccines, Synthetic / immunology*

Substances

  • ALS1 protein, Candida albicans
  • Fungal Proteins
  • Fungal Vaccines
  • Recombinant Proteins
  • Vaccines, Synthetic